 |
(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Trigeminal neuralgia |
| USA Market Approval | USA |
| USA Designation Date | 2013-07-24 00:00:00 |
| Sponsor | Biogen, Inc.;300 Binney Street;Cambridge, Massachusetts, 02142 |
